Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan
Background: Afatinib and Osimertinib are first-line treatments for EGFR-mutated advanced non-small cell lung cancer (NSCLC), but their comparative efficacies and the patient groups that benefit the most remain unclear. This multicenter retrospective study evaluated the efficacy of first-line Afatini...
Zapisane w:
| Główni autorzy: | , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
MDPI AG
2025-01-01
|
| Seria: | Current Oncology |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.mdpi.com/1718-7729/32/1/36 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|